On September 26, Ingenuity is sponsoring a free webinar hosted by The Scientist magazine. Presenting will be Dr. Milan Radovich, assistant professor in the Department of Surgery at the Indiana University School of Medicine, who will discuss study data from the RNA-sequencing of triple-negative breast cancers (TNBCs).
TNBCs—defined as those lacking receptors for estrogen, progesterone and human epidermal growth factor—account for some 15 percent of all U.S. breast cancer cases. Because of the absence of therapeutic targets, these patients on average have a poorer overall survival rate compared to other breast cancer subtypes.
Using RNA-Seq and Ingenuity Pathway Analysis (IPA), Dr. Radovich and his colleagues were able to perform a comprehensive network and pathway analysis which revealed novel insights into the tumor biology of this disease and helped inform follow-on investigations of drug targets that may aid in the development of much needed therapies for treating TNBCs.
This webinar will cover:
- How to quickly and easily interpret RNA-Seq gene-expression data in a biological context based on relevant findings from the literature
- How to adopt an integrated approach to statistical and biological analysis that will allow rapid identification of key pathways, processes, and diseases related to differentially expressed genes
- How to use novel approaches to quickly customize analysis results and identify findings most relevant to your research
Please join us on Thursday, September 26, 2013 from 2:30 – 3:30 p.m. Eastern Time; you can register online here. The webinar is free and open to anyone interested in this important area of cancer research.
About Dr. Radovich
Dr. Milan Radovich is an assistant professor in the Department of Surgery at the Indiana University School of Medicine. He is also a member of the IU Simon Cancer Center, the IU Center for Computational Biology and Bioinformatics, and the Indiana Institute for Personalized Medicine. His research focuses on the use of next-generation sequencing in translational oncology. In particular, his laboratory concentrates on the use of next-generation sequencing for drug development and pharmacogenomics, and for understanding mutational causes of cancer. In addition, a major focus of his work is the integration of next-generation sequencing into cancer clinical trials, with a special focus on using genomics for precision medicine.